Loxo Oncology Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Loxo Oncology (LOXO) Reports Q2 Loss of $1.64, Revenues Beat
August 9, 2018 6:49 AM EDTLoxo Oncology (NASDAQ: LOXO) reported Q2 EPS of ($1.64), versus ($0.54) reported last year. Revenue for the quarter came in at $42.6 million versus the consensus estimate of $28.91 million.
We made significant progress across our pipeline in the second quarter, said Josh Bilenker, M.D., chief... More
